Ion Channels: New Actors Playing in Chemotherapeutic Resistance

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Mar 20

PMID 30884858

Citations 29

Authors

Philippe Kischel

Alban Girault

Lise Rodat-Despoix

Mohamed Chamlali

Silviya Radoslavova

Hiba Abou Daya

Thibaut Lefebvre

Arthur Foulon

Pierre Rybarczyk

Frederic Hague

Isabelle Dhennin-Duthille

Mathieu Gautier

Halima Ouadid-Ahidouch

Affiliations

Soon will be listed here.

Abstract

In the battle against cancer cells, therapeutic modalities are drastically limited by intrinsic or acquired drug resistance. Resistance to therapy is not only common, but expected: if systemic agents used for cancer treatment are usually active at the beginning of therapy (i.e., 90% of primary breast cancers and 50% of metastases), about 30% of patients with early-stage breast cancer will have recurrent disease. Altered expression of ion channels is now considered as one of the hallmarks of cancer, and several ion channels have been linked to cancer cell resistance. While ion channels have been associated with cell death, apoptosis and even chemoresistance since the late 80s, the molecular mechanisms linking ion channel expression and/or function with chemotherapy have mostly emerged in the last ten years. In this review, we will highlight the relationships between ion channels and resistance to chemotherapy, with a special emphasis on the underlying molecular mechanisms.

Citing Articles

Extracellular Matrix Cues Regulate Mechanosensing and Mechanotransduction of Cancer Cells.

Mierke C Cells. 2024; 13(1).

PMID: 38201302 PMC: 10777970. DOI: 10.3390/cells13010096.

Targeting K3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells.

Todesca L, Gerke M, Bulk E, Bachmann M, Rudersdorf A, Antonuzzo L Cell Death Discov. 2024; 10(1):2.

PMID: 38177097 PMC: 10767088. DOI: 10.1038/s41420-023-01776-5.

Association of and GLUR4 Ion Transporters with Neoadjuvant Chemoresistance in Luminal Locally Advanced Breast Cancer.

Justo-Garrido M, Lopez-Saavedra A, Alcaraz N, Cortes-Gonzalez C, Onate-Ocana L, Caro-Sanchez C Int J Mol Sci. 2023; 24(22).

PMID: 38003293 PMC: 10670992. DOI: 10.3390/ijms242216104.

Beyond matrix stiffness: targeting force-induced cancer drug resistance.

Kalli M, Poskus M, Stylianopoulos T, Zervantonakis I Trends Cancer. 2023; 9(11):937-954.

PMID: 37558577 PMC: 10592424. DOI: 10.1016/j.trecan.2023.07.006.

Potassium Channels, Glucose Metabolism and Glycosylation in Cancer Cells.

Wawrzkiewicz-Jalowiecka A, Lalik A, Lukasiak A, Richter-Laskowska M, Trybek P, Ejfler M Int J Mol Sci. 2023; 24(9).

PMID: 37175655 PMC: 10178682. DOI: 10.3390/ijms24097942.

References

Mason R . Effects of calcium channel blockers on cellular apoptosis: implications for carcinogenic potential. Cancer. 1999; 85(10):2093-102. DOI: 10.1002/(sici)1097-0142(19990515)85:10<2093::aid-cncr1>3.0.co;2-e. View

Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier M, Krakowski I . Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol. 2001; 11(11):1471-6. DOI: 10.1023/a:1026556119020. View

Berridge M, Lipp P, Bootman M . The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol. 2001; 1(1):11-21. DOI: 10.1038/35036035. View

Marklund L, Henriksson R, Grankvist K . Cisplatin-induced apoptosis of mesothelioma cells is affected by potassium ion flux modulator amphotericin B and bumetanide. Int J Cancer. 2001; 93(4):577-83. DOI: 10.1002/ijc.1363. View

Vanden Abeele F, Skryma R, Shuba Y, Van Coppenolle F, Slomianny C, Roudbaraki M . Bcl-2-dependent modulation of Ca(2+) homeostasis and store-operated channels in prostate cancer cells. Cancer Cell. 2002; 1(2):169-79. DOI: 10.1016/s1535-6108(02)00034-x. View

Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S . Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002; 2(3):183-92. DOI: 10.1016/s1535-6108(02)00127-7. View

Orrenius S, Zhivotovsky B, Nicotera P . Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003; 4(7):552-65. DOI: 10.1038/nrm1150. View

Vanoverberghe K, Vanden Abeele F, Mariot P, Lepage G, Roudbaraki M, Bonnal J . Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ. 2003; 11(3):321-30. DOI: 10.1038/sj.cdd.4401375. View

Liang X, Yin J, Zhou J, Wang P, Taylor B, Cardarelli C . Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. Exp Cell Res. 2004; 293(2):283-91. DOI: 10.1016/j.yexcr.2003.10.012. View

10.

Padar S, van Breemen C, Thomas D, Uchizono J, Livesey J, Rahimian R . Differential regulation of calcium homeostasis in adenocarcinoma cell line A549 and its Taxol-resistant subclone. Br J Pharmacol. 2004; 142(2):305-16. PMC: 1574945. DOI: 10.1038/sj.bjp.0705755. View

11.

Marklund L, Andersson B, Behnam-Motlagh P, Sandstrom P, Henriksson R, Grankvist K . Cellular potassium ion deprivation enhances apoptosis induced by cisplatin. Basic Clin Pharmacol Toxicol. 2004; 94(5):245-51. DOI: 10.1111/j.1742-7843.2004.pto940508.x. View

12.

Huang Y, Anderle P, Bussey K, Barbacioru C, Shankavaram U, Dai Z . Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 2004; 64(12):4294-301. DOI: 10.1158/0008-5472.CAN-03-3884. View

13.

Schaaf A, Sagi S, Langbein S, Trojan L, Alken P, Michel M . Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol Oncol. 2004; 22(3):188-92. DOI: 10.1016/j.urolonc.2004.01.010. View

14.

Tsunoda T, Koga H, Yokomizo A, Tatsugami K, Eto M, Inokuchi J . Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines. Oncogene. 2004; 24(8):1396-402. DOI: 10.1038/sj.onc.1208313. View

15.

Parekh A, Putney Jr J . Store-operated calcium channels. Physiol Rev. 2005; 85(2):757-810. DOI: 10.1152/physrev.00057.2003. View

16.

Chen S, Jiang M, Zhen Y . HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin. Cancer Chemother Pharmacol. 2005; 56(2):212-20. DOI: 10.1007/s00280-004-0960-5. View

17.

Marin M, Poret A, Maillet G, Leboulenger F, Le Foll F . Regulation of volume-sensitive Cl- channels in multi-drug resistant MCF7 cells. Biochem Biophys Res Commun. 2005; 334(4):1266-78. DOI: 10.1016/j.bbrc.2005.07.010. View

18.

Huang Y, Sadee W . Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett. 2005; 239(2):168-82. DOI: 10.1016/j.canlet.2005.07.032. View

19.

Liang X, Taylor B, Cardarelli C, Yin J, Annereau J, Garfield S . Different roles for K+ channels in cisplatin-resistant cell lines argue against a critical role for these channels in cisplatin resistance. Anticancer Res. 2005; 25(6B):4113-22. View

20.

Ise T, Shimizu T, Lee E, Inoue H, Kohno K, Okada Y . Roles of volume-sensitive Cl- channel in cisplatin-induced apoptosis in human epidermoid cancer cells. J Membr Biol. 2005; 205(3):139-45. DOI: 10.1007/s00232-005-0779-y. View